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EDITORIAL
A refined understanding of immunosuppressives and cancer risk
Following organ transplantation a variety of immuno- tor [6] for antigen while the molecular target of the rap-
suppressive regimens are used to prevent acute and chronic amycin-FKBP-12 complex is TOR, a central controller
rejection. The immunosuppressive protocols most often of cell growth and an important member of many growth
employ daily treatment with two or three drugs. Most of- factor signaling pathways [7].
ten a calcineurin inhibitor is given with either mycophe- Luan et al [2] note the effects of rapamycin on tumor
nolate mofetil or sirolimus or (less often) azathioprine and cell growth, apoptosis, and the expression of two soluble
corticosteroids. Many centers also use poly- or monoclo- factors that are known to be overexpressed in renal cell
nal antibodies immediately following transplantation. A carcinoma growth, namely, vascular endothelial growth
heightened risk for development of certain malignant dis- factor (VEGF-A) and TGF-1. They find that rapamy-
eases is an unfortunate consequence that attends the use of cin dramatically decreases pulmonary metastases, whereas
long-term immunosuppression [1]. While the use of po- CsA increases them and, moreover, that rapamycin re-
tent biologic agents such as polyclonal antilymphocyte verses the CsA effect. As expected based on their earlier
antibodies as an adjunct to standard drug therapy adds to data [4], rapamycin arrested renal cell carcinoma cells
risk of developing neoplasia, there has been no compelling in the G1 phase of the cell cycle. In agreement with the
evidence that the choice of any of the particular conven- publication by Guba et al [5], rapamycin diminished the
tional drugs adds or detracts from the overall heightened expression of VEGF-A by the tumor cells. Finally, circu-
risk of developing posttransplant malignant conditions re- lating VEGF-A and TGF-1 levels were lower in rapa-
sulting from the various long-term immunosuppressive mycin-treated mice.
regimens. However, preclinical data now suggest that it There are numerous intriguing features of this study
will be most important to examine the incidence of cancer by Luan et al [2], as well as several unanswered questions.
in patients with respect to the particularity of the drug Unfortunately, the paper did not assess rapamycin levels
regimens. It seems likely that considerations in addition in the blood. It would be particularly important to know
to the magnitude of overall immunosuppression must be if, at the doses of rapamycin utilized in vivo, the blood
considered in assessing the risk to develop and disseminate concentrations were below immunosuppressive levels,
cancers and lymphomas in transplant recipients. As a pro- for example 10 ng/mL. For example, at these low levels,
logue to the study reported in this issue of Kidney Interna- the authors have previously shown striking effects on pro-
tional by Luan et al [2], this same group has previously liferation of renal cancer cells in vitro. Also unanswered
noted that cyclosporine (CsA) has a tumor-promoting ac- is the question of how pertinent this effect is in malignant
tivity linked to the drugs’ ability to promote transforming diseases other than renal cell carcinoma, although the
growth factor- (TGF-) expression [3]. paper by Guba et al [5] utilized a colon cancer line and
The paper by Luan et al [2] is a logical sequel to two early papers have used several other lines [8, 9]. Thus,
other articles, one from the same group published earlier the question of whether renal cell cancers are particularly
this year [4], showing that rapamycin can block tumor pro- susceptible to rapamycin inhibition needs to be addressed
gression, and an article by Guba et al [5] demonstrating in future studies. Of note, the rapamycin analog CCI-779
that rapamycin can inhibit both primary and metastatic is showing some activity in advanced renal cell carcinoma
tumor growth by antiangiogenic mechanisms. The cur- in early studies (abstract #36; Atkins MB et al, ASCO
rent paper focuses on metastatic disease. The authors uti- 2002 Meeting).
lize a renal cell carcinoma pulmonary metastasis model The mechanisms by which rapamycin exerts effects on
using human renal carcinoma cells in a SCID beige mouse both the tumor and on the endothelial cell compartments
to evaluate the effects of rapamycin or CsA alone or rap- in a cancer warrant more investigation. Clearly, there are
amycin and CsA in combination on the development of effects on cell-cycle progression in the tumor cell and
pulmonary metastases and survival. CsA, a stimulant of rapamycin can also reverse, in part, the mesenchymal phe-
TGF- [3], acts to block the calcium-dependent intracel- notype of invasive tumor cells, as shown by its ability to
lular signal resulting from activation of the T cell recep- induce E-cadherin in renal cancer cells [4]. However, lit-
tle is known of the detailed signaling involved in this pro-
cess. Rapamycin also blunts VEGF and TGF-1 intra-Key words: organ transplantation, transforming growth factor-, cyclo-
sporine, vascular endothelial growth factor. cellular signaling effects. The authors have not assessed a
third cytokine that is also well known to be up-regulated 2003 by the International Society of Nephrology
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inhibitor of human renal cancer metastasis. Kidney Int 63:917–926,in renal cell carcinoma, namely, TGF-, against which ther-
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apies are being designed in renal cell carcinoma [10]. In 3. Hojo M, Morimoto T, Maluccio M, et al: Cyclosporine induces
cancer progression by a cell autonomous mechanism. Nature 397:renal cell carcinoma, over 80% carry mutation or hyper-
530–534, 1999methylation of the von Hippel-Lindau (VHL) tumor sup-
4. Luan FL, Hojo M, Maluccio M, et al: Rapamycin blocks tumor
pressor gene, resulting in stabilization of hypoxia-induc- progression: Unlinking immunosuppression from antitumor effi-
cacy. Transplantation 73:1565–1572, 2002ible factor-1a (HIF-1a) and subsequent overexpression
5. Guba M, von Breitenbuch P, Steinbauer M, et al: Rapamycinof VEGF-A, TGF-1, and TGF- [10]. A unifying hypoth-
inhibits primary and metastatic tumor growth by antiangiogenesis:
esis to explain this data would be to position mTOR up- Involvement of vascular endothelial growth factor. Nat Med 8:128–
135, 2002stream of HIF-1a, and downstream of activation of nu-
6. Schreiber SL, Crabtree GR: The mechanism of action of cyclospo-merous receptor kinases and hypoxia. Several recent rin A and FK506. Immunol Today 13:136–142, 1992
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Cell 103:253–262, 2000Finally, the effects of rapamycin on the endothelial cell
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stream activator of mTOR via Akt) is clearly important ular mechanisms and newer therapeutic options. Curr Opin Nephrol
Hypertens 1:37–42, 2002[15, 16]. The role of this pathway in mediating other pro-
11. Mayerhofer M, Valent P, Sperr WR, et al: BCR/ABL inducesangiogenic cytokine signals needs to be elucidated. Fi-
expression of vascular endothelial growth factor and its transcrip-
nally, it will be of great importance to carefully examine tional activator, hypoxia inducible factor-1alpha, through a path-
way involving phosphoinositide 3-kinase and the mammalian targettransplant registry data for evidence to support or refute
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